NanoBio Corp.

NanoBio® is a biopharmaceutical company focused on developing and commercializing topical and mucosal antimicrobial products derived from its patented NanoStat™ technology platform.

The researcher/inventor is James R. Baker, Jr. MD, the CSO of NanoBio® Corporation. At the University of Michigan, Dr. Baker is the Ruth Dow Doan Professor at the School of Medicine; Chief, Division of Allergy; and Director of the University of Michigan Nanotechnology Institute for Medicine and Biomedical Studies (M-NIMBS).

NanoBio's commercial product pipeline consists of six promising pharmaceuticals. The company's two lead products are treatments for cold sores (herpes labialis) and nail fungus (onychomycosis). Treatments for MRSA, genital herpes, and shingles, are in varying stages of development.

In addition, a vaccine prototype based on the NanoStat platform not requiring refrigeration or the use of needles is being developed for NanoBio by M-NIMBS. This effort is funded by a $6.3 million grant. NanoBio owns rights to all intellectual property related to the product and will direct development after the clinical proof-of-concept is completed by M-NIMBS. The technology also has the potential for facilitating a wide range of additional products including nasal spray vaccines.

Primary Activity